Roivant Sciences

Roivant Sciences Provides Corporate Updates in Advance of First Annual Pipeline Day

Retrieved on: 
Tuesday, July 10, 2018
Roivant Sciences, Genentech, Biotechnology, Economy, Business

-- Myrtle Potter, former President and COO of Genentech, appointed Vant Operating Chair

Key Points: 
  • -- Myrtle Potter, former President and COO of Genentech, appointed Vant Operating Chair
    BASEL, Switzerland and NEW YORK, July 10, 2018 /PRNewswire/ -- Roivant Sciences announced a series of corporate updates across the Roivant family of companies in advance of its first annual Pipeline Day this afternoon in New York City.
  • Axovant announced the expansion of its gene therapy pipeline with the addition of AXO-AAV-OPMD for the treatment ofoculopharyngeal muscular dystrophy.
  • Preliminary clinical data from an ongoing Phase 1 study for RVT-1401 will be presented later today at Pipeline Day.
  • Roivant Pipeline Day will be held on Tuesday, July 10, 2018 in New York City.

Myovant Sciences to Present at First Annual Roivant Pipeline Day

Retrieved on: 
Monday, June 18, 2018
Vivek Ramaswamy, Roivant Sciences

BASEL, Switzerland, June 18, 2018 /PRNewswire/ -- Myovant Sciences (NYSE:MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Lynn Seely, M.D., President and Chief Executive Officer of Myovant Sciences, will present at the first annual Roivant Pipeline Dayon July 10, 2018 at 2:30 p.m.

Key Points: 
  • BASEL, Switzerland, June 18, 2018 /PRNewswire/ -- Myovant Sciences (NYSE:MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Lynn Seely, M.D., President and Chief Executive Officer of Myovant Sciences, will present at the first annual Roivant Pipeline Dayon July 10, 2018 at 2:30 p.m.
  • Roivant Pipeline Day will be held on Tuesday, July 10, 2018 in New York City.
  • Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases.
  • Over time, Myovant intends to expand its development pipeline to include other potential treatments for women's health and endocrine diseases.

Roivant Expands Senior Leadership with Key Hires

Retrieved on: 
Wednesday, May 16, 2018
Vivek Ramaswamy, Pfizer, Roivant Sciences, Business, Biotechnology, Economy of New York City

"I would like to extend a warm welcome to Sam and Adele," said Vivek Ramaswamy, Founder and Chief Executive Officer of Roivant Sciences.

Key Points: 
  • "I would like to extend a warm welcome to Sam and Adele," said Vivek Ramaswamy, Founder and Chief Executive Officer of Roivant Sciences.
  • Dr. Azoulay joins Roivant from Pfizer, where he most recently served as Senior Vice President and Chief Medical Officer for Pfizer Essential Health.
  • He has over 25 years of experience in the biopharmaceutical industry and has held senior leadership roles at Pfizer since 2001, including Head of Development in Japan and Senior Vice President for Medical and Development in Emerging Markets.
  • Roivant partners with innovative biopharmaceutical companies and academic institutions to ensure that important medicines are rapidly delivered to patients.

monARC Bionetworks Announces Strategic Integration with Roivant Drug Development Platform to Accelerate Delivery of New Medicines

Retrieved on: 
Thursday, May 3, 2018
Pharmaceutical industry, Biotechnology, Health, Nature, Roivant Sciences, Biopharmaceutical, Medication, Drug development

"Our core strategy of putting patients first has reduced clinical research timelines," said Komathi Stem, Founder and CEO of monARC.

Key Points: 
  • "Our core strategy of putting patients first has reduced clinical research timelines," said Komathi Stem, Founder and CEO of monARC.
  • "Roivant's drug development team supports the companies in our family as they develop innovative medicines in their respective therapeutic areas," said William T. Symonds, PharmD, Chief Development Officer at Roivant.
  • Roivant Sciences is a global biopharmaceutical company focused on reducing the time and cost of the drug development process to improve the lives of patients and their families.
  • Roivant partners with innovative biopharmaceutical companies and academic institutions to ensure that important medicines are rapidly delivered to patients.